+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 120Years
All Genders
ID05003895

Study of Anti-GPC3 CAR-T Cell Therapy for Adults With Advanced GPC3-Positive Solid Tumors

Led by National Cancer Institute (NCI) · Updated on 2026-10-16

38

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a personalized immune treatment called anti-GPC3 CAR-T cells for adults with advanced Glypican-3 GPC3 positive solid tumors, including hepatocellular carcinoma and other solid tumor malignancies. This phase I study aims to assess the safety and feasibility of these modified T cells that are designed to target cancer cells expressing GPC3, a protein found on tumor cells but not on normal adult liver tissue. Participants undergo a detailed screening process including blood and urine tests, medical history review, physical examination, heart function tests, tumor biopsy, and imaging scans of the chest, abdomen, and pelvis. Eligible participants have their white blood cells collected through leukapheresis, followed by a hospital stay of about two weeks. During hospitalization, they receive chemotherapy with fludarabine and cyclophosphamide for three days and then an infusion of the modified CAR-T cells. The study involves escalating doses of CAR-T cells to determine the maximum tolerated dose. Throughout the study, participants have frequent blood draws and provide blood and tumor samples for research. Follow-up visits occur regularly for the first year after infusion, with continued monitoring for up to 15 years and ongoing contact for life. Imaging studies take place every six months if the disease remains stable after five years. The main outcome measured is the safety and feasibility of the CAR-T cell treatment over a 15-year period, along with assessing tumor response and overall survival.

CONDITIONS

Brief Title

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Research Team

D

Donna Hrones, C.R.N.P.

T

Tim F Greten, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here